Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Trinity Biotech ( (TRIB) ).
On March 23, 2026, Trinity Biotech announced successful clinical results for an enhanced version of its EpiCapture prostate cancer test, which now uses a machine learning algorithm that integrates DNA biomarkers with patient features such as ethnicity to improve prediction of aggressive disease. The urine-based liquid biopsy aims to provide a less invasive and more accessible alternative to MRI scans and needle biopsies, addressing disparities in diagnostic performance across demographic and ethnic groups.
In an independently conducted study of about 750 patient samples from a larger and more diverse cohort, the upgraded EpiCapture test achieved an AUC of 85%, a level considered strong in oncology diagnostics, and the company plans to submit these findings for publication in a peer-reviewed journal. Trinity Biotech intends to commercialize EpiCapture as a proprietary laboratory developed test through its New York State-certified reference laboratory, marking its first strategic move into precision oncology diagnostics and reinforcing its broader pivot toward data-driven, multimodal precision medicine solutions.
Separately, the company disclosed that it obtained a limited waiver related to covenant 8.15 of its credit agreement with Perceptive Credit Holdings III, allowing interest accruing in March 2026 to be capitalized and added to the principal balance of its debt. The waiver offers near-term financial flexibility as Trinity Biotech advances commercialization plans for EpiCapture and continues its innovation agenda in high-burden disease areas.
The most recent analyst rating on (TRIB) stock is a Hold with a $0.80 price target. To see the full list of analyst forecasts on Trinity Biotech stock, see the TRIB Stock Forecast page.
Spark’s Take on TRIB Stock
According to Spark, TipRanks’ AI Analyst, TRIB is a Neutral.
Overall score is held down primarily by weak financial performance (sharp TTM revenue decline, deep losses, negative equity, and negative free cash flow). Technicals are only mildly supportive with mixed trend signals, and valuation provides limited support due to a negative P/E and no dividend yield data.
To see Spark’s full report on TRIB stock, click here.
More about Trinity Biotech
Trinity Biotech plc is a commercial-stage biotechnology and diagnostics company focused on diabetes management solutions, human diagnostics and wearable biosensors. It develops, acquires, manufactures and markets diagnostic systems, including reagents and instruments, for point-of-care and clinical laboratories, and sells its products in the U.S. and more than 75 countries through direct sales and distribution partners.
The company has recently expanded into the wearable biosensor industry by acquiring assets from Waveform Technologies Inc., and plans to develop a range of biosensor devices and related services, starting with continuous glucose monitoring. Its portfolio also includes tests for infectious diseases and assays to quantify haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood, underscoring its presence across key segments of the global diagnostics market.
Average Trading Volume: 328,663
Technical Sentiment Signal: Strong Sell
Current Market Cap: $11.3M
See more insights into TRIB stock on TipRanks’ Stock Analysis page.